Mounjaro video reviews

Patient testimonial covering six months on Mounjaro, with attention to titration cadence and protein habits that supported lean-mass retention.

• Lost 45 lbs in 6 months — front-loaded in months 2-4
• Stuck on each titration step for 6 weeks (not 4) to ease GI
• 120-140 g protein/day preserved muscle per DEXA scan

Our take: Strong real-world case with measurable outcomes — DEXA verification is a nice touch.

Educational deep-dive on why tirzepatide outperforms pure GLP-1 agonists in head-to-head trials — the GIP angle.

• Tirzepatide co-activates GIP + GLP-1 receptors (dual agonism)
• GIP arm appears to enhance lipid handling + insulin sensitivity
• SURMOUNT-1 head-to-head: tirzepatide outperformed semaglutide

Our take: Best explainer we have found on why tirzepatide hits harder than semaglutide.

A nurse practitioner walks through expected vs concerning side effects on Mounjaro, with clear escalation criteria.

• Mild-moderate nausea + bloating: expected, usually self-resolves
• Severe upper-abdominal pain → suspect pancreatitis, seek care
• Persistent vomiting >24h → dehydration risk, contact provider

Our take: Clear escalation thresholds — exactly the framework patients need on day one.

Clinical review of the SURPASS-2 trial comparing tirzepatide and semaglutide for T2D outcomes.

• SURPASS-2: tirzepatide 15 mg vs semaglutide 1 mg head-to-head
• HbA1c reduction: tirzepatide -2.30% vs semaglutide -1.86%
• Weight loss: tirzepatide -11.2 kg vs semaglutide -5.7 kg

Our take: Crisp, well-cited walkthrough of the trial that reshaped clinical GLP-1 prescribing.

News + how-to walkthrough on appealing a Mounjaro denial, including appeal letter templates.

• Most denials stem from missing diagnosis code or PA paperwork
• External appeal success rates are ~50% with full documentation
• Letters of medical necessity carry significant weight

Our take: Practical playbook — pair with our coverage + provider tools.